06.07.2020 SHOP APOTHEKE EUROPE N.V.  NL0012044747



DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Preliminary Results/Development of Sales

06.07.2020 / 07:00
The issuer is solely responsible for the content of this announcement.


  • Outstanding quarter with sales growth of 42%, fully organic.
  • Preliminary sales growth of DACH segment 33% and of International segment 105% in Q2.
  • Record number of new active customers; up 0.5 million in Q2 to 5.5 million.
  • Construction of new logistics centre and headquarters on track.

Venlo, 6 July 2020. SHOP APOTHEKE EUROPE N.V. has continued to achieve strong growth during the second quarter of 2020, preliminary calculations show. Consolidated revenues rose by 42% to EUR 233 million in Q2 after EUR 164 million during the same period last year. On a year-to-date basis, preliminary sales at Group level increased by 37% to EUR 465 million after EUR 338 million in H1 2019. The number of active customers rose to 5.5 million as of 30 June, 2020, an increase of 0.5 million compared to the end of Q1 and by 0.8 million YTD.

Stefan Feltens, CEO of SHOP APOTHEKE EUROPE, comments: "We are really proud of our achievements this quarter. In this very challenging environment, due to the impact of the coronavirus pandemic on society, we were able to serve more customers than ever in all of the seven countries we operate in. Customer satisfaction was again remarkably high reflecting our dedication to provide the best pharmacy service. Online pharmacies further strengthened their role as an important and complementary part of the healthcare system by providing support and safeguarding the supply of medications to patients. Looking forward, I am happy to once again confirm that we are on track with our new distribution facility which will lead to a more than doubling of our capacity."

In Q2, the DACH segment (Germany, Austria, Switzerland) revenues were increased by 33% compared to the corresponding period of the previous year. Revenues were EUR 190 million after EUR 143 million in the second quarter of 2019. During the first half of 2020, DACH sales grew by 31% to EUR 391 million (previous year: EUR 298 million).

The International segment (Belgium, Italy, France, the Netherlands) more than doubled its Q2 sales by 105% to EUR 42 million compared to EUR 21 million in Q2 2019 and by 83% to EUR 74 million during the first half of 2020 (previous year: EUR 40 million).

The prescription drugs (Rx) business increased by 13% versus Q2 2019 and by 18% in H1. Growth continued, but was lower in Q2 compared to Q1 (+23%) since many people stocked up on medications in the first quarter. Furthermore, social distancing and improved hygiene have resulted in lower transmission of communicable diseases and therefore in lower demand for prescription drugs.

Jasper Eenhorst, CFO of SHOP APOTHEKE EUROPE, says: "After a strong start into the year, we have been able to further accelerate our growth during Q2. While the surges in demand in March were strongly driven by more orders from existing customers, we gained record numbers of new customers in the second quarter when we successfully acted upon the momentum. All in all, we are well ahead of our initial forecast. Similar to Q1, based upon our current estimates, we expect that the strong top-line as well as our continued focus on yielding efficiencies, and leveraging effects of scale will benefit our EBITDA for Q2. Growth in the upcoming two quarters might be lower due to capacity reasons in our current facility."

The construction of the new distribution facility in Sevenum near Venlo continues to progress according to plan. Most office functions will be transferred to the new facility by the end of July. First orders are expected to be processed at the new site before the end of 2020. The logistic operations will be completely relocated during the first half of 2021. Following the relocation, SHOP APOTHEKE EUROPE will have more than doubled its capacity to meet the rapidly growing customer demand expected in the coming years.

All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE will release the full interim report for the first half of 2020 on 6 August 2020.


SHOP APOTHEKE EUROPE is one of the leading and the fastest-growing online pharmacies in Continental Europe. With the acquisition of Europa Apotheek Venlo in November 2017, SHOP APOTHEKE EUROPE significantly extended its European market leadership. The product range for the whole family in the OTC, beauty and personal care products as well as prescription drugs segments is supplemented by high quality natural food and health products, low carb products and sports nutrition following the acquisition of nu3 GmbH in July 2018.

SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to 5.5 million active customers fast and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive pharmaceutical consulting services.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016 and is part of the SDAX index since 24 September 2018.

In addition to being traded on the Frankfurt stock exchange, SHOP APOTHEKE EUROPE'S convertible bonds (ISIN: DE000A19Y072) are also tradeable on the Dutch Euronext stock exchange, which operates the stock exchanges in Paris, Amsterdam, Brussels and Lisbon.



Trade and popular media:
Sven Schirmer
Tel: +49 221 99 53 44 31
Email: presse@shop-apotheke.com

Financial media:
Bettina Fries
Tel: +49 211 75 80 779
Email: presse@shop-apotheke.com

Investor relations:
Carmen Herkenrath
Tel.: +31 77 850 6109
Email: carmen.herkenrath@shop-apotheke.com

Thomas Schnorrenberg
Mobile: +49 151 465 31317
Email: presse@shop-apotheke.com


This publication constitutes an advertisement. This announcement does not constitute an offer for sale or a solicitation of an offer to purchase securities of SHOP APOTHEKE EUROPE N.V. in any jurisdiction. It does not constitute a securities prospectus. A public offer of securities of SHOP APOTHEKE EUROPE N.V. is not taking place.

Statements contained herein could constitute so-called "forward-looking statements". Forward-looking statements can be recognized by words such as "might," "will," "should," "plans," "anticipates," "anticipates," "estimates," "believes," "intends," "aims," "aim" or their negative form or corresponding modifications and comparable terms.

Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the actual results, levels of utilization, developments and achievements of the group or industry in which it operates to be materially different than those contained herein or implied. There should be no undue reliance on forward-looking statements. The group will not update or revise any forward-looking statements contained herein, whether as a result of new information, future events or otherwise.

06.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Dirk Hartogweg 14
5928 LV Venlo
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: carmen.herkenrath@shop-apotheke.com
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y07
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1086533

End of News DGAP News Service

1086533  06.07.2020 


Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019 2020e
Umsatzerlöse1 55,29 84,67 125,58 177,39 283,99 539,71 701,01 939,00
EBITDA1,2 -0,75 -2,39 -6,65 -8,84 -12,14 -15,56 -18,58 20,30
EBITDA-Marge3 -1,36 -2,82 -5,30 -4,98 -4,27 -2,88 -2,65 2,16
EBIT1,4 -1,88 -4,05 -8,82 -11,64 -19,20 -28,73 -33,45 0,00
EBIT-Marge5 -3,40 -4,78 -7,02 -6,56 -6,76 -5,32 -4,77 0,00
Jahresüberschuss1 -2,83 -5,04 -10,58 -18,45 -21,36 -33,61 -36,27 0,00
Netto-Marge6 -5,12 -5,95 -8,42 -10,40 -7,52 -6,23 -5,17 0,00
Cashflow1,7 -4,24 -3,68 -8,78 -17,21 -23,24 -23,54 -30,37 0,00
Ergebnis je Aktie8 -0,31 -0,56 -1,16 -2,03 -2,25 -2,79 -2,78 -0,70
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

Shop Apotheke Europe
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2AR94 149,600 Halten 2.676,37
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,000 -90,83
8,94 - 3,82 -145,973
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
0,00 0,00 0,00 30.04.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
14.05.2020 06.08.2020 05.11.2020 17.03.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
2,03% 54,06% 241,16% 301,61%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SHOP APOTHEKE EUROPE N.V.  ISIN: NL0012044747 können Sie bei DGAP abrufen

E-Commerce , A2AR94 , SAE , XETR:SAE